Progress in therapeutic monoclonal antibodies targeting hepatitis B surface antigen / 中华微生物学和免疫学杂志
Chinese Journal of Microbiology and Immunology
; (12): 805-810, 2021.
Article
in Zh
| WPRIM
| ID: wpr-912117
Responsible library:
WPRO
ABSTRACT
Chronic hepatitis B (CHB) is often treated with drugs such as interferons and nucleoside (acid)/nucleotide (acid) analogs. While these drugs are effective in controlling the viral loads, they are not able to eliminate hepatitis B virus (HBV) from the body completely. Besides, side effects and drug resistance may by caused by the long-term use of these drugs. Several monoclonal antibodies (McAbs) against HBV, mostly against hepatitis B surface antigen (HBsAg), have been demonstrated with viral neutralization capability and with effective inhibition of HBV replication in relevant animal models. The use of a McAb individually or in combination with another therapy has the potentials to achieve functional cure of CHB. In this review, we summarized the encouraging results from the research and development of anti-HBV McAbs in clinical or pre-clinical development stage, aiming to provide new idea for the treatment of CHB.
Full text:
1
Database:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Microbiology and Immunology
Year:
2021
Document type:
Article